The effects of curcuminoid on esophageal and gastric function in patients with gastroesophageal reflux disease

Government Pharmaceutical Organization (GPO)0 个研究点目标入组 20 人开始时间: 2018年5月30日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

•1. Patients who have been diagnosed with acid reflux for at least 3 months
•2. Age 18 - 70 years
•3. Have had gastrointestinal endoscopy in the last 6 months prior to study.
•4. The results of acid measurement in the esophagus found that acid reflux in the esophagus is excessive.

•1. Surgery in the abdomen except appendicitis, Maternity leave
•2. Cancer of the gastrointestinal tract and liver
•3. chronic inflammatory bowel disease inflammatory bowel disease
•4. Cirrhosis, Chronic kidney disease
•5. Depression
•6. Upper gastrointestinal endoscopy results in 6 months before admission. The following abnormalities were observed: esophagus, gastric ulcer and duodenal ulcer.
•7. Helicobacter pylori infection
•8. Patients who take the drug with gastrointestinal effects and can not off the drug during research.
•9. There are neurological diseases that can not be evaluated for pain. Uncontrolled psychiatric disorders and may want to adjust the drugs during study.
•10. Have allergic curcumin.
•11. Eat foods that component curcumin, regularly at least 3 days a week during the 1 month prior to study
•12. Patients who can not sign the consent form for study participation.

发起方

Government Pharmaceutical Organization (GPO)